STARHEALTH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.5
| Stock Code | STARHEALTH | Market Cap | 30,614 Cr. | Current Price | 520 ₹ | High / Low | 587 ₹ |
| Stock P/E | 55.0 | Book Value | 163 ₹ | Dividend Yield | 0.00 % | ROCE | 8.57 % |
| ROE | 6.70 % | Face Value | 10.0 ₹ | DMA 50 | 482 ₹ | DMA 200 | 466 ₹ |
| Chg in FII Hold | 0.99 % | Chg in DII Hold | -0.65 % | PAT Qtr | 111 Cr. | PAT Prev Qtr | 128 Cr. |
| RSI | 65.6 | MACD | 16.2 | Volume | 4,99,736 | Avg Vol 1Wk | 24,48,724 |
| Low price | 341 ₹ | High price | 587 ₹ | PEG Ratio | -15.9 | Debt to equity | 0.05 |
| 52w Index | 72.8 % | Qtr Profit Var | 21,731 % | EPS | 9.47 ₹ | Industry PE | 31.6 |
📊 Analysis: STARHEALTH shows weak profitability metrics with ROCE at 8.57% and ROE at 6.70%. Valuation is expensive (P/E 55 vs industry 31.6), and PEG ratio (-15.9) indicates poor growth prospects relative to valuation. Dividend yield is absent (0.00%), limiting income support. Technicals are moderately strong (RSI 65.6, MACD positive, price above DMA 50 & 200). Quarterly profit declined (111 Cr vs 128 Cr), raising concerns about earnings consistency. Debt-to-equity is low (0.05), which adds financial stability. Overall, STARHEALTH is financially stable but faces valuation and profitability challenges.
💰 Entry Price Zone: Ideal accumulation range is ₹470–₹490, closer to DMA support levels. Avoid chasing above ₹530 until earnings momentum improves.
📈 Exit / Holding Strategy: Existing holders should maintain a medium-term horizon (2–3 years). Consider partial exit near ₹560–₹580 if valuations expand. Dividend yield is absent, so capital appreciation must drive returns. Monitor quarterly earnings and sector demand for sustained holding.
✅ Positive
- Low debt-to-equity ratio (0.05).
- Price trading above DMA 50 & 200, showing technical strength.
- FII holdings increased (+0.99%).
⚠️ Limitation
- Weak ROE (6.70%) and ROCE (8.57%).
- High valuation (P/E 55 vs industry 31.6).
- PEG ratio (-15.9) indicates poor growth prospects.
📉 Company Negative News
- Quarterly PAT declined (111 Cr vs 128 Cr).
- DII holdings reduced (-0.65%).
📈 Company Positive News
- EPS at 9.47 ₹ supports valuation stability.
- Quarterly profit variation shows strong YoY improvement (21,731%).
🏦 Industry
- Industry PE at 31.6, lower than STARHEALTH’s 55.
- Health insurance sector benefits from rising demand and regulatory support.
- Competition and margin pressures remain challenges.
🔎 Conclusion
STARHEALTH is a moderately weak candidate for long-term investment due to poor profitability and high valuation. Entry near ₹470–₹490 offers better risk-reward. Suitable for medium-term investors, but long-term holding requires significant improvement in ROE and earnings consistency. Monitoring profitability and sector dynamics is essential before committing to extended holding.